Compare Allegion PLC (ALLE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allegion PLC vs Twist Bioscience Corp — how do they compare? Allegion PLC trades at $136.63 (market cap $11.74B), while Twist Bioscience Corp trades at $90 (market cap $5.64B). The key difference: Allegion PLC is far larger — about 2.1× Twist Bioscience Corp's market cap, and Allegion PLC pays a 1.55% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| ALLE | TWST | |
|---|---|---|
Market Cap | $11.74B | $5.64B |
Sector | Industrials | Health |
52-Week High | $179.77 | $102.88 |
52-Week Low | $125.65 | $24.16 |
Enterprise Value | $13.46B | $5.57B |
Dividend Yield | 1.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $136.63, up 1.15% today, with a bearish technical signal but strong profitability metrics including a 15.24% net income margin and 34.18% ROE. Recent earnings missed estimates in Q1 2026, but revenue growth remains steady, reaching $4.07B in 2025. The company continues innovation with new product launches like the Schlage Sense Pro smart deadbolt, supporting long-term growth in security solutions.
The stock presents a mixed outlook: analyst consensus is a $152.50 price target with a 'Hold' bias, offering potential upside, but technical weakness and recent earnings misses pose near-term risks. Investors should weigh strong fundamentals against execution challenges and macroeconomic pressures affecting margins.
Twist Bioscience (TWST) trades at $90.64, down 3.24% today, with a bullish technical signal from moving averages and ADX indicators. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a net income margin of -19.85%. Recent developments include AI-driven drug discovery collaborations and expansion of clonal genes offerings, positioning TWST in the growing synthetic biology market.
While analyst consensus is strongly bullish (77% buy ratings) with a $87.88 price target, investors face significant risks from persistent cash burn and competitive pressures. The stock's valuation appears stretched at 13.46x sales despite negative earnings, requiring careful monitoring of path to profitability and execution on AI partnerships for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
